RxDoctor Payments Data

Ashok Dayal, MD

Internal Medicine · Gallipolis, OHNPI 1134174485

Payments from drug & device makers

$3,485in general payments, 2019–2025

Across 218 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$441
  • AbbVie$403
  • GSK$330
  • Pfizer$291
  • Novo Nordisk$251
  • Boehringer Ingelheim$230
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$3,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,485 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$98,868
Medicare patients
323
Services billed
1,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin115$133,099
OzempicSemaglutide93$94,074
EliquisApixaban105$90,586
TrulicityDulaglutide81$83,532
FarxigaDapagliflozin Propanediol53$54,218
JanuviaSitagliptin Phosphate37$39,707
TradjentaLinagliptin30$25,172
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,279
XareltoRivaroxaban14$15,778
EntrestoSacubitril/Valsartan15$13,089
Breo ElliptaFluticasone/Vilanterol13$7,950
Atorvastatin Calcium718$7,095
Xigduo XrDapaglifloz Propaned/Metformin12$6,876
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$6,801
SymbicortBudesonide/Formoterol Fumarate20$6,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$230$158,271145 claims
Novo NordiskOzempic$251$94,07493 claims
PfizerEliquis$291$90,586105 claims
Lilly USA, LLCTrulicity$165$83,53281 claims
AstraZenecaFarxiga, Symbicort$195$60,44373 claims
MerckJanuvia$106$39,70737 claims
GSKTrelegy Ellipta, Breo Ellipta$330$25,22935 claims
Johnson & JohnsonXarelto$125$15,77814 claims
NovartisEntresto$87$13,08915 claims
AbbVieSynthroid$403$2,28169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Gallipolis

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →